Back to Search
Start Over
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
- Source :
- Cancer Weekly. December 24, 2024, 43
- Publication Year :
- 2024
-
Abstract
- 2024 DEC 24 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Nektar Therapeutics (Nasdaq: NKTR) announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as [...]
Details
- Language :
- English
- ISSN :
- 15324567
- Database :
- Gale General OneFile
- Journal :
- Cancer Weekly
- Publication Type :
- News
- Accession number :
- edsgcl.820857396